Magrolimab plus Azacitidine Versus Azacitidine plus Placebo in Untreated Higher Risk Myelodysplastic Syndrome: The Phase 3, Randomized, ENHANCE Study

被引：0

作者：

Garcia-Manero, Guillermo ^{[1
]}

Daver, Naval ^{[1
]}

Xu, Jin ^{[2
]}

Chao, Mark ^{[2
]}

Chung, Trisha ^{[2
]}

Tan, Anderson ^{[2
]}

Wang, Yan ^{[2
]}

Wei, Andrew ^{[3
,4
]}

Vyas, Paresh ^{[5
]}

Sallman, David ^{[6
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[3] Alfred Hosp, Melbourne, Vic, Australia

[4] Monash Univ, Melbourne, Vic, Australia

[5] Univ Oxford, Oxford, England

[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2021年 / 96卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PO-1

引用

页码：S3 / S3

页数：1

共 50 条

[21] Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)
Garcia-Manero, Guillermo
Scott, Bart L.
Kishtagari, Ashwin
Sanikommu, Srinivasa R.
Al-Kali, Aref
Lee, Je-Hwan
Burgues, Juan M. Bergua
Diez-Campelo, Maria
Erba, Harry P.
Garcia-Hernandez, Carmen
Santillana, Guillermo Sanz
O'Connell, Casey
Jang, Jun-Ho
Shin, Dong-Yeop
Sayar, Hamid
Rao, Mayank
Schwartz, Richard S.
An, Grace
Jin, Feng
Forgie, Alison J.
Tsiatis, Athanasios C.
Altman, Jessica K.
CANCER RESEARCH, 2024, 84 (07)
[22] Phase 2, Randomized, Double-Blind Study of Pracinostat in Combination With Azacitidine in Patients With Untreated, Higher-Risk Myelodysplastic Syndromes
Garcia-Manero, Guillermo
Montalban-Bravo, Guillermo
Berdeja, Jesus G.
Abaza, Yasmin
Jabbour, Elias
Essell, James
Lyons, Roger M.
Ravandi, Farhad
Maris, Michael
Heller, Brian
DeZern, Amy E.
Babu, Sunil
Wright, David
Anz, Bertrand
Boccia, Ralph
Komrokji, Rami S.
Kuriakose, Philip
Reeves, James
Sekeres, Mikkael A.
Kantarjian, Hagop M.
Ghalie, Richard
Roboz, Gail J.
CANCER, 2017, 123 (06) : 994 - 1002
[23] Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome
Narayan, Rupa
Garcia, Jacqueline S.
Percival, Mary-Elizabeth M.
Berube, Caroline
Coutre, Steve
Gotlib, Jason
Greenberg, Peter
Liedtke, Michaela
Hewitt, Rhonda
Regan, Kathleen
Williamson, Charles
Doykan, Camille
Cardone, Michael H.
McMillan, Alex
Medeiros, Bruno C.
LEUKEMIA & LYMPHOMA, 2016, 57 (03) : 609 - 615
[24] Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results
Sallman, David
Al Malki, Monzr
Asch, Adam
Wang, Eunice
Jurcic, Joseph
Bradley, Terrence
Flinn, Ian
Pollyea, Daniel
Kambhampati, Suman
Tanaka, Tiffany
Zeidner, Joshua
Garcia-Manero, Guillermo
Jeyakumar, Deepa
Gu, Lin
Tan, Anderson
Chao, Mark
O'Hear, Carol
Lal, Indu
Vyas, Paresh
Daver, Naval
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S314 - S315
[25] A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
Desikan, Sai Prasad Prasad
Montalban-Bravo, Guillermo
Ohanian, Maro
Daver, Naval
Yilmaz, Musa
Konopleva, Marina
Kadia, Tapan M.
Venugopal, Sangeetha
Schneider, Heather
Chien, Kelly S.
Kanagal-Shamanna, Rashmi
Kantarjian, Hagop
Garcia-Manero, Guillermo
BLOOD, 2021, 138 : 3704 - +
[26] Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML (vol 35, pg 2119, 2021)
Sekeres, Mikkael A.
Watts, Justin
Radinoff, Atanas
Sangerman, Montserrat Arnan
Cerrano, Marco
Lopez, Patricia Font
Zeidner, Joshua F.
Campelo, Maria Diez
Graux, Carlos
Liesveld, Jane
Selleslag, Dominik
Tzvetkov, Nikolay
Fram, Robert J.
Zhao, Dan
Bell, Jill
Friedlander, Sharon
Faller, Douglas V.
Ades, Lionel
LEUKEMIA, 2021, 35 (12) : 3637 - 3637
[27] A Phase 3, Randomized Trial of Magrolimab in Combination With Venetoclax and Azacitidine in Previously Untreated Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy (ENHANCE-3)
Daver, Naval
Liu, Ke
Werneke, Scott
Rustia, Evelyn
Ramsingh, Giri
Vyas, Paresh
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S5 - S5
[28] Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome
Chien, Kelly S.
Borthakur, Gautam
Naqvi, Kiran
Daver, Naval
Bravo, Guillermo Montalban
Cortes, Jorge E.
DiNardo, Courtney D.
Jabbour, Elias
Alvarado, Yesid
Andreeff, Michael
Bose, Prithviraj
Jain, Nitin
Sheppard, Kimberly
Klingner-Winton, Cheri
Pierce, Sherry A.
Dong, Xiao Qin
Soltysiak, Kelly A.
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
BLOOD, 2020, 136
[29] Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.
Sallman, David Andrew
Al Malki, Monzr M.
Asch, Adam Steven
Wang, Eunice S.
Jurcic, Joseph G.
Bradley, Terrence J.
Flinn, Ian W.
Pollyea, Daniel Aaron
Kambhampati, Suman
Tanaka, Tiffany N.
Zeidner, Joshua F.
Garcia-Manero, Guillermo
Jeyakumar, Deepa
Gu, Lin
Tan, Anderson
Chao, Mark
O'Hear, Carol Elaine
Lal, Indu
Vyas, Paresh
Daver, Naval Guastad
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[30] Randomized Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia or Low-Blast Acute Myeloid Leukemia: Exploratory Analysis of Patient-Reported Outcomes
Zeidner, Joshua F.
Mazerolle, Flora
Bell, Jill A.
Cain, Lauren E.
Faller, Douglas V.
Dalal, Mehul
Regnault, Antoine
Fram, Robert J.
BLOOD, 2020, 136

← 1 2 3 4 5 →